Wednesday - December 25, 2024

LOGIN  |  REGISTER
Amneal Pharmaceuticals
Recursion

Editas Medicine to Participate in Upcoming Investor Conferences

November 06, 2024 | Last Trade: US$1.24 0.01 -0.80

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December:

  • Guggenheim’s Inaugural Healthcare Innovation Conference
    Format: Fireside Chat
    Date: Tuesday, November 12
    Time: 4:00 p.m. ET
    Location: Boston, MA
  • Stifel 2024 Healthcare Conference
    Format: Fireside Chat
    Date: Tuesday, November 19
    Time: 1:50 p.m. ET
    Location: New York, NY
  • 7th Annual Evercore ISI HealthCONx Conference
    Format: Fireside Chat
    Date: Tuesday, December 3
    Time: 1:20 p.m. ET
    Location: Coral Gables, FL

To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.

About Editas Medicine

As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Astria Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB